OR WAIT null SECS
The addition of Biodesix’s Nodify Lung nodule risk assessment tool to Philips’ lung cancer patient management system may enhance diagnostic efficiency and facilitate improved management of high-risk patients.
In the ongoing quest to expedite timely intervention for patients with lung cancer and rein in the amount of biopsies on benign nodules, Philips has added Nodify Lung (Biodesix), a blood-based risk assessment tool for lung nodules, to the company’s Lung Cancer Orchestrator system.
Philips said the Nodify Lung testing detects the presence of blood-based biomarkers and provides proteomic data that may provide adjunctive value to clinical and radiomic assessment in the classification of malignancy risk.
“By incorporating Biodesix’s Nodify Lung testing, we take another step in leveraging integrated diagnostics from imaging, genomics, and now proteomic results from a simple blood draw to address key moments in the lung cancer patient journey, support care team decision-making, and help health systems learn from their practice patterns in a dashboard view,” said Louis Culot, the general manager of oncology informatics and genomics at Philips.
“We are delighted that our tests are being incorporated into Philips’ vision for end-to-end cancer care management using a multi-diagnostic approach,” said Scott Hutton, the president and chief executive officer at Biodesix. “By integrating our Nodify® tests in Philips Lung Cancer Orchestrator, we hope to make these tests more accessible to physicians and patients and more easily utilized by care teams with the ultimate goal of improving patient care and outcomes.”
Philips said the Lung Cancer Orchestrator, an integrated patient management system that can be utilized for computed tomography (CT) lung cancer screening programs as well as incidental findings of lung nodules, enables physicians to keep track of imaging findings, appointments, and clinical decisions.